Company evaluating site location to further culture of innovation and collaboration
AstraZeneca today announced Delaware will remain the headquarters of its North America Commercial business which plays a critical role in delivering AstraZeneca’s strategy and organizational priorities.
Paul Hudson, President, AstraZeneca US and Executive Vice President, North America said: “Delaware provides a great environment for our employees as we continue to deliver innovative biopharmaceuticals that benefit millions of patients. At the same time, our company and culture have evolved since AstraZeneca’s presence first started in the state over 15 years ago. Creating an even more vibrant work environment that furthers our evolving culture of innovation and collaboration, while staying in the state we’ve proudly called home, allows us to leverage our legacy and continue building new capabilities for the future.”
AstraZeneca is in the process of looking at whether to redesign its current office space or relocate to another nearby location in Delaware. Timing for a decision is expected later this year and is dependent on a thorough review of all options available and conversations with third parties.
NOTES TO EDITORS
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology – as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please www.astrazeneca-us.com.
|Abigail Bozarth||+1 302 885 2677|